Skip to main content

Medicine Matters oncology


  • Patients with unresectable or metastatic disease
  • (Adjuvant therapy) Patients with stage III disease
  • (In combination with nivolumab) Patients with BRAF V600 wild-type unresectable or metastatic disease

Renal cell carcinoma

  • (In combination with nivolumab) Previously untreated patients with intermediate- and poor-risk advanced disease

Colorectal cancer

  • (In combination with nivolumab) Adult and pediatric patients ≥12 years old with microsatellite instability high or mismatch repair-deficient metastatic disease